Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy

Kälviäinen, Reetta; Äikiä, Marja; Mervaala, Esa; Saukkonen, Anna Maija; Pitkänen, Asla; Riekkinen, Paavo

doi:10.1016/s0920-1211(96)00084-8

Cited by 61 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adjustment of therapy led to an increase in TGB dose, with a daily dose within the range of 30-80 mg (mean 66 mg). However, despite this increase, no cognitive deterioration was found (30).…”

Section: Safety and Tolerabilitymentioning

confidence: 84%

Review of Controlled Trials of Gabitril (Tiagabine): A Clinician's Viewpoint

Loiseau

1999

Epilepsia

View full text Add to dashboard Cite

Summary: A recent problem for doctors has been the choice of which new antiepileptic drug (AED) to select for treatment of pharmacoresistant epilepsy. This article summarizes the clinical experience to date regarding the efficacy and safety of tiagabine (TGB; Gabitril) as adjunctive therapy in patients with partial-onset seizures. In its early Phase I1 development, TGB was evaluated in two multicenter pilot studies. Each had an open-label enrichment phase followed by a treatment phase with randomized, double-blind, two-period, cross-over phases. Between 24 and 50% of patients experienced reductions in seizure rates of ?500/0, depending on the type of partial seizure. In Phase 111, three double-blind, parallel group, placebocontrolled adjunctive studies determined the efficacy of TGB in patients with refractory partial seizures. The first was a doseresponse study employing doses of TGB-HCI of 16, 32 or 56 mg/day. Significant reductions in seizure rates were found with 32 and 56 mg/day. The second and third studies evaluated the efficacy of dosing TGB twice, three times, and four times daily, all of which showed similar efficacy. TGB efficacy in partial seizures was supported in several open trials, and no tolerance to efficacy was noted in long-term continuation studies. Tolerability was documented in all trials. Most adverse events were mild or moderate and transient, occurring during dose titration. They were clearly dose-related. No relevant changes in hematologic and biochemical tests, vital signs, or body weight were attributable to TGB. TGB appears to be an effective new drug for partial seizures with an acceptable safety profile.

show abstract

Section: Safety and Tolerabilitymentioning

confidence: 84%

Review of Controlled Trials of Gabitril (Tiagabine): A Clinician's Viewpoint

Loiseau

1999

Epilepsia

View full text Add to dashboard Cite

show abstract

“…38,51,152,153,168,169 One study used GBP, 90 two used LTG 55,88 and three used TGB. 39,43,167 No studies of LEV, OXC or TPM were found.…”

Section: E Cognitive Functionmentioning

confidence: 99%

“…One of three 39,43,167 studies found that one cognitive score (Form F of the Benton Visual Retention Test) out of 37 favoured placebo compared with adjunctive TGB 167 …”

Section: Tgbmentioning

confidence: 99%

“…Only six studies failed to do so. 40,[43][44][45][46][47] Five of these studies were reported in abstract form only. 40,[44][45][46][47] 4.…”

mentioning

confidence: 99%

“…64 The majority of studies (93) accounted for all patients and six did not. 43,[65][66][67][68][69] Twelve studies, including eight abstracts, 40,41,[44][45][46][47]59,60 provided insufficient information. In four studies, one of which was an abstract, 61 all patients were accounted for in some, but not all, outcome assessments.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Wilby¹,

Kainth²,

Hawkins³

et al. 2005

Health Technol Assess

199

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

Treatment of epilepsy in the multiply handicapped

Pellock

Morton

2000

Ment. Retard. Dev. Disabil. Res. Rev.

View full text Add to dashboard Cite

The medical management of epilepsy in the multi‐handicapped patient requires careful evaluation, classification, and pharmacologic treatment. It is estimated that 20–40% of patients with mental retardation and cerebral palsy have epilepsy. This review reports the clinical trial data and personal experience related to the use of newer AEDs in the chronic management of epilepsy syndromes in children and adults, as well as information available on the treatment of seizures in individuals with mental retardation and associated handicaps. Furthermore, clusters of seizures, prolonged seizures and status epilepticus are more commonly seen in the multiply handicapped and mentally retarded population and require special attention. The new antiepileptic drugs felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide show specific advantage in some multiply handicapped patients, be it for seizure control or medication tolerance. Furthermore, new modalities of treatment for prolonged seizures allow better efficacy both outside of hospital and within hospital facilities. The treatment of epilepsy in multi‐handicapped and retarded adults and children has significantly advanced in the past few years, and much of this improvement can be attributed to improved knowledge and monitoring of new antiepileptic drugs. Conventional anticonvulsants remain first line therapy for most clinicians, but newer AEDs must broaden the therapeutic option and do allow improved therapy for some multiply handicapped patients. MRDD Research Reviews 2000;6:309–323. © 2000 Wiley‐Liss, Inc.

show abstract

Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy

Cited by 61 publications

References 16 publications

Review of Controlled Trials of Gabitril (Tiagabine): A Clinician's Viewpoint

Review of Controlled Trials of Gabitril (Tiagabine): A Clinician's Viewpoint

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Treatment of epilepsy in the multiply handicapped

Contact Info

Product

Resources

About